The occurrence and development of tumors are related to the disorder of intracellular signal transduction, especially the disorder of signal transduction pathway of receptor tyrosine kinase (RTK). Protein kinase inhibitors acting on this pathway can suppress the intracellular transmission of proliferation signals of tumor cells, thereby controlling their proliferation. Protein tyrosine kinase-mediated signal transduction pathway is currently an antitumor drug target which is studied by many researchers and demonstrates significant effects. Besides, as the main anti-tumor drug type available on market in recent years, multi-target tyrosine kinase inhibitors can inhibit multiple signal transduction pathways, induce the apoptosis of tumor cells, blocks the formation of new blood vessels, and inhibits the proliferation of tumor cells. Therefore, this paper reviews the relationship between tyrosine kinases and tumors, commercially available typical tyrosine kinase inhibitors, and their application prospects.
REFERENCES
1.
Shawver
LK
, Salmon
D
, Ullrich
A.
Smart drugs: tyrosine kinase inhibitors in cancer therapy
. Cancer Cell
2002
; 1
(2
): 117
–23
.2.
Traxler
P
, Bold
C
, Buchdunger
E
, et al Tyrosine kinase inhibitors: from rational design to clinical trials
. Med. Res. Rev
2001
; 21
(6
): 499
–512
.3.
Fabbro
D
, Ruetz
S
, Buchdunger
E
, et al Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
. Pharmacol. Ther.
2002
, 93
(2-3
): 79
–98
.4.
Blume-Jensen
P
, Hunter
T.
Oncogenic kinase signalling
. Nature
, 2001
, 411
(6835
): 355
–65
.5.
Mao
Z Q
, Xiang
W Z
, Yan
Y U
, et al Review on the research development of small molecular protein tyrosine kinases inhibitors[J]
. Chinese Journal of Medicinal Chemistry
, 2005
.6.
Zhang
J
, Yang
P L
, Gray
N S.
Targeting cancer with small molecule kinase inhibitors [J]
. Nat Rev Cancer
, 2009
, 9
(1
): 28
–39
.7.
Moen
MD
, McKeage
K
, Plosker
GL
, et al Imatinib: a review of its use in chronic myeloid leukaemia [J]
. Drugs
, 2007
, 67
(2
):299
–320
.8.
Iyer
R
, Fetterly
G
, Lugade
A
, et al Sorafenib: a clinical and pharmacologic review [J]
. Expert Opinion on Pharmacotherapy
, 2010
, 11
(11
):1943
–1955
.FDA Approves Nexavar for Patients with Inoperable Liver Cancer. FDA.gov. 2007-11-19.9.
FDA Approves Nexavar for Patients with Inoperable Liver Cancer. FDA.gov. 2007-11-19.
10.
FDA approves new treatment for gastrointestinal and kidney cancer.
2006
.11.
Hartmann
JT
, Kanz
L.
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition
. Arch Dermatol.
November 2008
, 144
(11
): 1525
–6
. PMID 19015436. doi:.12.
Gastrointestinal stromal tumor: a clinical overview
. Hematol. Oncol. Clin. North Am.
February 2009
, 23
(1
): 69
–78
, viii. PMID 19248971. doi:.13.
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations
. Expert Rev Anticancer Ther.
June 2009
, 9
(6
): 831
–8
. PMID 19496720. doi:.14.
Sunitinib in solid tumors
. Expert Opin Investig Drugs.
June 2009
, 18
(6
): 821
–34
. PMID 19453268. Doi: .15.
Prescribing information for Sutent (sunitinib malate)
. Pfizer, Inc
, New York NY
.16.
Kantarjian
H
; et al … Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
. N Engl J Med.
2006
, 354
(24
): 2542
–51
. PMID 16775235. Doi: .17.
Patients with treatment-resistant leukemia achieve high responses to Tasigna (nilotinib) in first published clinical trial results
. MediaReleases (Novartis)
. 2006-06-14 [2009-08-04].18.
Weisberg
E
, Manley
P
, Mestan
J
, Cowan-Jacob
S
, Ray
A
, Griffin
JD
. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
. Br. J. Cancer. June
2006
, 94
(12
): 1765
–9
. PMC 2361347. PMID 16721371. doi:.19.
Arun
A A
, Emma
K B
, Sebastian
J H
, et al A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in pa-tients with chemotherapy na ve castration-resistant prostate cancer [J]
. Invest New Drug
, 2014
, 32
(4
):746
–752
.20.
Geyer
CE
, Forster
J
, Lindquist
D
et al Lapatinib plus capecitabine for HER2-positive advanced breast cancer
. N Engl J Med
2006
; 355
: 2733
–43
.21.
Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more
”. Medscape Reference
. WebMD. Retrieved 27 January 2014.22.
CHMP Assessment Report: Votrient (pazopanib)” (PDF)
. European Medicines Agency.
Retrieved 8 October 2016.23.
VOTRIENT (pazopanib hydrochloride) tablet, film coated [GlaxoSmithKline LLC]” (PDF)
. DailyMed. GlaxoSmithKline LLC.
November 2013. Retrieved 27 January 2014.24.
Votrient: EPAR - Product Information” (PDF)
. European Medicines Agency. Glaxo Group Ltd.
23 January 2014. Retrieved 27 January 2014.25.
Mesa
, Ruben A.
; Yasothan
, Uma
; Kirkpatrick
, Peter
(2012
). “Ruxolitinib
”. Nature Reviews Drug Discovery.
11
(2
): 103
–4
. Doi: . PMID 22293561.26.
Harrison
, C
; Mesa
, R
; Ross
, D
; Mead
, A
; Keohane
, C
; Gotlib
, J
; Verstovsek
, S
(2013
). “Practical management of patients with myelofibrosis receiving ruxolitinib
”. Expert Review of Hematology.
6
(5
): 511
–23
. doi:. PMID 24083419.27.
Highlights of Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202192s012lbl.Pdf.28.
Vannucchi
AM
, Kiladjian
JJ
, Griesshammer
M
et al (2015
). “Ruxolitinib versus standard therapy for the treatment of polycythemia vera
”. N. Engl. J. Med.
372
(5
): 426
–35
. Doi: . PMC 4358820. PMID 25629741.29.
Mesa
RA
(2010
). “Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
”. IDrugs.
13
(6
): 394
–403
. PMID 20506062.30.
Pardanani
, A.
; Tefferi
, A.
(2011
). “Targeting myeloproliferative neoplasms with JAK inhibitors
”. Current Opinion in Hematology.
18
(2
): 105
–10
. doi:. PMID 21245760.31.
Harrison
, C.
; Kiladjian
, J. J.
; Al-Ali
, H. K.
; Gisslinger
, H.
; Waltzman
, R.
; Stalbovskaya
, V.
; McQuitty
, M.
; Hunter
, D. S.
; Levy
, R.
; Knoops
, L.
; Cervantes
, F.
; Vannucchi
, A. M.
; Barbui
, T.
; Barosi
, G.
(2012
). “JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
”. New England Journal of Medicine.
366
(9
): 787
–798
. Doi: . PMID 22375970.32.
Verstovsek
, S.
; Mesa
, R. A.
; Gotlib
, J.
; Levy
, R. S.
; Gupta
, V.
; Dipersio
, J. F.
; Catalano
, J. V.
; Deininger
, M.
; Miller
, C.
; Silver
, R. T.
; Talpaz
, M.
; Winton
, E. F.
; Harvey Jr
, J. H.
; Arcasoy
, M. O.
; Hexner
, E.
; Lyons
, R. M.
; Paquette
, R.
; Raza
, A.
; Vaddi
, K.
; Erickson-Viitanen
, S.
; Koumenis
, I. L.
; Sun
, W.
; Sandor
, V.
; Kantarjian
, H. M.
(2012
). “A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
”. New England Journal of Medicine.
366
(9
): 799
–807
. Doi: . PMC 4822164. PMID 22375971.33.
Tefferi
, A.
(2012
). “Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
”. New England Journal of Medicine.
366
(9
): 844
–846
. Doi: . PMID 22375977.34.
ASCO Annual Meeting 2011: JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis Archived November 21, 2011, at the Wayback Machine.
35.
“
FDA Approves Incyte’s Jakafi (ruxolitinib) for Patients with Myelofibrosis
” (Press release). Incyte.
Retrieved 2012-01-02.36.
FDA approval letter
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202192Orig1s008ltr.pdf.37.
Massimo
B
, Matteo
M
, Giuliana
A.
How tyrosine kinase in-hibitors impair metabolism and endocrine system function:A sys-tematic updated review [J]
. Leukemia Res
, 2014
, 38
(12
):1392
–1398
.38.
39.
Sawyr
T K
, Wu
J C
, Sawyer
J R
, et al Protein kinase in-hibitors: Breakthrough medicines and the next generation [J]
. Expert Opin Invest Drugs
, 2013
, 22
(6
):675
–678
.
This content is only available via PDF.
© 2019 Author(s).
2019
Author(s)
